PREVENTION OF PATHOLOGICAL TAU ABNORMALITIES BY NON-ANTIBIOTIC DERIVATIVES OF DEMECLOCYCLINE AND OXYTETRACYCLINE.

MICHEL, PATRICK P.; ALVES, T; TOMAS GRAU, RH; TOURVILLE, A; ANDRETTO DE MATOS, B; GONZALEZ LIZARRAGA, MF; CISS, I; CHEHÍN, R; FERRIE, L; FIGADERE, B; DEL-BEL, E; RAISMAN VOZARI, R

Lisbon

Conferencia; AD/PD? 2024 International Conference on Alzheimer?s and Parkinson?s Diseases and related neurological disorders; 2024

We established, here, experimental paradigms enabling the investigation of tau-related abnormalities (pathological phosphorylation, amyloid aggregation)occurring in Alzheimer’s disease (AD) and other tauopathies to evaluate the therapeutic potential of anti-tau molecules for these disorders. More specifically, we wereinterested in characterizing the effects of 12a-deoxy-dedimethylamino-demeclocycline (DDMC) and 12a-deoxy-dedimethylamino-oxytetracycline (DOT), two non-antibiotictetracycline (TC) derivatives of demeclocycline and oxytetracycline, respectively.